rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
SNCA rs11931074 polymorphism is found to be associated with PD risk and this risk appears to be influenced by genetic status and ethnicity.
|
31758346 |
2020 |
rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
In an interaction analysis, SNP rs11931074-PD status interaction was significantly associated with positive α-Syn immunostaining in the ENS (OR = 7.33, 95% CI = 1.58-33.88, P = 0.01).
|
30424941 |
2019 |
rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
Also blood sample of each participant was genotyped for rs11931074 polymorphism (PD: TT = 19, GT = 32, GG = 11; HC: TT = 10, GT = 25, GG = 12) and then examined to ascertain the influence of different genotypes on regional brain activity with amplitude low-frequency fluctuation analysis (ALFF).
|
31243602 |
2019 |
rs356219
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
Further subgroup analysis showed that PD+RBD patients with rs356219/G exhibited a 30% and 20% decreased risk of progression on the H-Y stage and MoCA score (<i>p</i> = 0.038; <i>p</i> = 0.045).
|
31244647 |
2019 |
rs356219
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
In the discovery series cohort, we found a 4-loci interaction involving STK11 rs8111699, FCHSD1 rs456998, GSK3B rs1732170, and SNCA rs356219, which was associated with an increased risk of PD (odds ratio = 2.59, P < .001).
|
31234232 |
2019 |
rs356219
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
The results indicate that there is a significant association between rs356219 polymorphism and PD susceptibility for all genetic models (allelic: OR = 1.377, 95% CI: 1.275-1.487, p = 0.000; homozygous: OR = 1.958, 95% CI: 1.666-2.301, p = 0.000; heterozygous: OR = 1.261, 95% CI: 1.158-1.373, p = 0.000; dominant: OR = 1.431, 95% CI: 1.320-1.550, p = 0.000; recessive: OR = 1.632, 95% CI: 1.431-1.861, p = 0.000), which is consistent with the results of the subgroup analyses on Asians and Caucasians.
|
31325583 |
2019 |
rs356219
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
The SNCA rs356219-G allele was found to increase the risk of PD in LRRK2 carriers (OR 1.50, 95%CI 1.08-2.01, P = 0.016), and the AAO of AG + GG genotypes was 4 years earlier than AA genotype (P = 0.006).
|
31041581 |
2019 |
rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
In conclusion, our meta-analysis further indicates that the SNCA rs11931074 polymorphism contributes to PD susceptibility.
|
30120622 |
2018 |
rs356219
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
An association with PD was shown for SNPs rs356219, rs11931074, rs356168.
|
30316070 |
2018 |
rs356219
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
The single-nucleotide polymorphism rs356219 in the α-synuclein (SNCA) gene has been shown to significantly contribute to an earlier age at onset of Parkinson's disease (PD), and regulates SNCA expression in PD brain regions, blood, and plasma.
|
29505953 |
2018 |
rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
The association of rs11931074 with decreased risk of PD was also significant.
|
26732583 |
2016 |
rs356219
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
Additionally, the SHEsis software platform was applied for linkage disequilibrium (LD) analysis between rs356182 and another PD-associated synuclein SNP rs356219 we previously reported.
|
27538639 |
2016 |
rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
Subgroup analysis of patients with both clinical and genetic results demonstrated that after adjusting for age, sex, chronic constipation and cpRBD, rs11931074 TT genotype may increase the risk of hyposmia in PD (OR = 3.24 95% CI = 1.23-8.51, p = 0.017) compared to GG genotype via an additive model.
|
25921825 |
2015 |
rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
Our results suggest that the rs3822086 (C) allele and rs11931074 (G) allele in SNCA decrease the risk for PD, and SNCA rs11931074 may affect frontal lobe dysfunction of MSA in the Chinese population.
|
26208350 |
2015 |
rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
We found that Rep1, rs356165, and rs11931074 in SNCA gene; G2385R in LRRK2 gene; rs4698412 in BST1 gene; rs1564282 in PARK17; and L444P in GBA gene were associated with PD with adjustment of sex and age (p < 0.05) in the analysis of 16 variants.
|
25623333 |
2015 |
rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms.
|
24418406 |
2014 |
rs356219
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
α-Synuclein rs356219 polymorphisms in patients with Gaucher disease and Parkinson disease.
|
25111979 |
2014 |
rs356219
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
GWASDB |
Identification of a novel Parkinson's disease locus via stratified genome-wide association study.
|
24511991 |
2014 |
rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
The SNP rs894278 confers risk via a dominant model and an additive model, whereas the minor allele G of rs11931074 reduces the risk of PD progression.
|
23853107 |
2013 |
rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
This study showed that two SNPs near the promoter region (rs2301134 and rs2301135) of SNCA gene gave the greatest evidence for an association with PD (p ≤ 0.01) and a haplotype block with two SNPs in the 3' UTR (rs356221 and rs11931074) revealed another evidence of association (p ≤ 0.02).
|
23182315 |
2013 |
rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
Of those, the SNCA SNP rs11931074 showed the most significant association with PD susceptibility (adjusted odds ratio = 1.48; 95% confidence interval = 1.31-1.67; p = 2.20E-10).
|
23820587 |
2013 |
rs356219
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
Our study provides strong support for the susceptibility role of SNCA rs356219 in sporadic PD in a Han Chinese population from mainland China and the meta-analysis also revealed a similar finding in the Asian population.
|
23737253 |
2013 |
rs11931074
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
GWASDB |
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database.
|
22438815 |
2012 |
rs356219
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
BEFREE |
The additive interactions between SNPs rs356219 and rs356220 and smoking with respect to sporadic PD were significant although the multiplicative interactions were not significant.
|
22425546 |
2012 |
rs356219
|
SNCA;LOC105377329
|
Parkinson Disease
|
|
0.900 |
GeneticVariation |
GWASCAT |
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database.
|
22438815 |
2012 |